Omeros Corporation is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing small-molecule and protein therapeutics. It targets large-market opportunities as well as orphan indications, particularly in areas such as inflammation, coagulopathies, disorders of the central nervous system, and complement-mediated diseases including immunologic disorders, cancers, and addictive and compulsive disorders. Notable product candidates include narsoplimab (OMS721), a monoclonal antibody inhibiting mannan-binding lectin-associated serine protease-2 to address the lectin pathway of complement, used for conditions like hematopoietic stem-cell transplant-associated thrombotic microangiopathy. The company also advances other pipeline assets like OMS1029 and MASP-3 inhibitors such as zaltenibart for rare diseases including paroxysmal nocturnal hemoglobinuria. Omeros Corporation operates within the health technology sector, emphasizing innovative treatments for unmet medical needs. Founded in 1994 and headquartered in Seattle, Washington, it plays a key role in advancing biopharmaceutical solutions for complex therapeutic challenges.